Debiopharm International

Debiopharm is a Swiss-based, family-owned biopharmaceutical company focused on the development of innovative therapies that target high unmet medical needs in oncology and infectious diseases. The company operates through a unique business model, in-licensing promising drug candidates, advancing them through clinical development, and then out-licensing them to global partners for commercialization. Their portfolio includes established products like oxaliplatin and triptorelin, alongside a robust pipeline of next-generation treatments such as antibody-drug conjugates and radiopharmaceuticals. Debiopharm also invests in digital health through its strategic investment arm to support the future of healthcare. The company maintains a strong manufacturing presence in Martigny, Switzerland, specializing in the production of complex small molecules and peptides.